Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: Experience in Hong Kong

Clinical Cardiology

Volumn 35, Issue 12, 2012, Pages

  Ho, Jason C S ^a   Chang, Andy M ^a   Yan, Bryan P ^a   Yu, Cheuk Man ^a   Lam, Yat Yin ^a   Lee, Vivian W Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN;

AGED; ANOREXIA; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONSTIPATION; DEATH; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSPNEA; FEMALE; FOLLOW UP; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HONG KONG; HUMAN; INSOMNIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL EDEMA; PREDICTION; PRESCRIPTION; PROPHYLAXIS; QUALITY OF LIFE; RETROSPECTIVE STUDY; THORAX PAIN; TREATMENT DURATION;

EID: 84870917997     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22069     Document Type: Article

References (22)

1. Wolf PA, Abbott RD, Kannel WB., Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991; 22: 983 -988.
2. Wolf PA, Abbott RD, Kannel WB., Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med. 1987; 147: 1561 -1564.
3. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31: 2369 -2429.
4. Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation. Chest. 2010; 137: 263 -272.
5. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999; 131: 492 -501.
6. Hart RG, Pearce LA, Aguilar MI., Meta analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146: 857 -867.
7. Singer DE, Albers GW, Dalen JE, et al. Antithromotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombotic Therapy. Chest. 2004; 126 (suppl): 429S -456S.
8. Ma TK, Yan BP, Lam YY., Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data. Pharmacol Ther. 2011; 129: 185 -194.
9. Kimmel SE, Chen Z, Price M, et al. The influence of patients adherence on anticoagulation control with warfarin. Arch Intern Med. 2007; 167: 229 -235.
10. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361: 1139 -1151.
11. Schulman S, Kearon C,; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thrombost Haemost. 2005; 3: 692 -694.
12. Rabin R, Oemar M, Oppe M, et al. EQ-5D-5L User Guide Version 1.0. EuroQol Group Executive Office; 2011. http://www.euroqol.org/fileadmin/user-upload/ Documenten/PDF/Folders-Flyers/UserGuide-EQ-5D-5L.pdf. Accessed August 5, 2012.
13. EuroQol Group, 2012. EQ-5D-5L crosswalk value sets. http://www.euroqol. org/fileadmin/user-upload/Documenten/Excel/Crosswalk-5L/EQ-5D-5L-Crosswalk- Value-Sets.xls. Accessed August 1, 2012
14. Wurster MW, Howard M, Price C, et al. Dabigatran use in the real world: preliminary results of a prospective trial comparing outcomes with dabigatran and warfarin therapy. Proceedings of the Thrombosis and Hemostasis Summit of North America: research abstracts. Am J Hematol. 2012; 87: S146 -S200.
15. Hughes S., Oral anticoagulants in the real world: bleeding rates and medical costs compared. The Heart.org. April 2, 2012. http://www.theheart.org/ article/1380849.do. Accessed August 5, 2012.
16. Cheung CM, Tsoi TH, Huang CY., The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation. Cerebrovasc Dis. 2005; 20: 114 -119.
17. Hori M, Connolly SJ, Ezekowitz MD, et al. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation-sub-analysis in Japanese population in RE-LY trial. Cir J. 2011; 75: 800 -805.
18. Shen AY, Yao JF, Brar SS, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007; 50: 309 -315.
19. Pradaxa (dabigatran etexilate) [package insert]. Hong Kong: Boehringer Ingelheim Ltd.; 2011.
20. US National Institutes, of Health. RELY-ABLE Long-Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial. 2012. http://www.clinicaltrials.gov/ct2/show/NCT00808067. Accessed August 5, 2012.
21. Lee VWY, You JHS, Lee KKC, et al. Factors affecting the Maintenance Stable Warfarin Dosage in Hong Kong Chinese Patients. J Thromb Thrombolysis. 2005; 20: 33 -38.
22. Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens. 2008; 10: 348 -354.